R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
Market Access One in five expressions of interest in UK regulator's pilot ... The MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme.
Patients Real-world evidence in CNS research: Past, present, future Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.
News Datavant, Aetion merger creates real-world data force Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.
News RFK Jr launches database project to explore autism causes A project to use federal databases to identify the "root causes of autism" has been launched by HHS, but there are concerns about its credibility.
R&D Supercharging clinical development with RWE – with Recursion... Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
